1. Home
  2. HRMY vs LMAT Comparison

HRMY vs LMAT Comparison

Compare HRMY & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • LMAT
  • Stock Information
  • Founded
  • HRMY 2017
  • LMAT 1983
  • Country
  • HRMY United States
  • LMAT United States
  • Employees
  • HRMY N/A
  • LMAT N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • LMAT Medical/Dental Instruments
  • Sector
  • HRMY Health Care
  • LMAT Health Care
  • Exchange
  • HRMY Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • HRMY 1.8B
  • LMAT 1.9B
  • IPO Year
  • HRMY 2020
  • LMAT 2006
  • Fundamental
  • Price
  • HRMY $33.53
  • LMAT $84.45
  • Analyst Decision
  • HRMY Strong Buy
  • LMAT Buy
  • Analyst Count
  • HRMY 9
  • LMAT 6
  • Target Price
  • HRMY $54.22
  • LMAT $100.80
  • AVG Volume (30 Days)
  • HRMY 626.9K
  • LMAT 151.4K
  • Earning Date
  • HRMY 08-05-2025
  • LMAT 07-31-2025
  • Dividend Yield
  • HRMY N/A
  • LMAT 0.95%
  • EPS Growth
  • HRMY 13.13
  • LMAT 30.45
  • EPS
  • HRMY 2.62
  • LMAT 1.97
  • Revenue
  • HRMY $744,852,000.00
  • LMAT $226,256,000.00
  • Revenue This Year
  • HRMY $20.10
  • LMAT $13.88
  • Revenue Next Year
  • HRMY $18.01
  • LMAT $8.81
  • P/E Ratio
  • HRMY $12.49
  • LMAT $42.77
  • Revenue Growth
  • HRMY 20.62
  • LMAT 13.19
  • 52 Week Low
  • HRMY $26.47
  • LMAT $71.42
  • 52 Week High
  • HRMY $41.61
  • LMAT $109.58
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 57.00
  • LMAT 55.03
  • Support Level
  • HRMY $31.70
  • LMAT $82.76
  • Resistance Level
  • HRMY $33.69
  • LMAT $84.72
  • Average True Range (ATR)
  • HRMY 0.88
  • LMAT 1.96
  • MACD
  • HRMY 0.11
  • LMAT 0.18
  • Stochastic Oscillator
  • HRMY 93.44
  • LMAT 82.43

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: